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Abstract: Primary human fetal brain neural stem cells (hNSCs) are a unique non-genetically
modified model system to study molecular mechanisms underlying human neural development,
to model human diseases, and to screen drugs or validate new treatments. They may also be used
for cell transplantation to treat various neurological diseases. This protocol details our methods
that can be used to expand hNSCs in culture as well as how to differentiate them into various
neuronal lineages and astrocytes.
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Understanding the regulation of neural stem cell proliferation, differentiation, and
survival is critical for developing treatments for a variety of developmental and neurodegenerative disorders. Many of the mechanisms governing these functions remain
poorly understood.1,2 Researchers have utilized animal models to study neurological
development and degeneration in vivo.3 While animal models have yielded valuable
information, they are both time consuming and genetically different from humans.
Researchers have also employed genetic manipulations to induce differentiated human
cells to become stem cells.4 These cells are commonly referred to as induced pluripotent stem cells. While these cells are human and have the advantage of being isolated
directly from patients, the genetic manipulations to induce pluripotency provide an
additional variable into an already complex system. In order to study some neurological
disorders, use of non-genetically modified primary human neural stem cells is optimal.
Human fetal brain neural stem cells (hNSCs) provide a unique culturing system to
understand the mechanisms governing hNSCs behavior without any genetic modifications. These cells can be expanded in culture and maintained as stem cells, or differentiated into various types of neurons and astrocytes. Culture of these cells has been used
in multiple studies ranging from infectious disease to amyotrophic lateral sclerosis.5–7
This system is particularly powerful if multiple donors can be found as individual
differences can be evaluated. However, the technical challenges associated with effect
and reproducible hNSC culture still present a barrier in the field. Even though many
people currently use similar growth factors, media, and isolation techniques, there is
considerable variability in hNSC behavior in culture over time among laboratories. This
cell culture is highly sensitive to chemical and mechanical manipulations, which can
greatly impact the quality of the culture and subsequent results. In order to enhance
reproducibility of hNSC study findings, we have developed specific protocols on how
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to handle and treat hNSCs to reduce cell death, premature
differentiation, and genetic mutation.
The following protocol details expansion and differentiation of hNSC populations, while emphasizing the technical
subtleties that will help reduce variation in results. We believe
this protocol is most helpful to investigators who wish to
establish hNSC cultures in their respective labs to address
a variety of projects concerning the impact of exogenous
stimuli on neural stem cell survival and differentiation. The
hNSCs used in this protocol were originally derived from
discarded human fetal cortexes in the first trimester, and their
isolation and initial expansion are described in a previous
publication.8 Following this initial expansion, vials of cells
were frozen and stored in liquid nitrogen; these are the vials
of cells used in this protocol. All protocol procedures adhere
to the University of Texas Medical Branch ethics guidelines
concerning the use of human tissue samples, and the cell
lines were approved by the Institutional Biosafety Committee.

Protocol

Media preparation and initial seeding
1. Before beginning the experiments, prepare a stock of
culture media.
a. 210 mL DMEM (D)
b. 70 mL F12 (F)
c. 4.2 mL HEPES buffer (H)
d. 4.2 mL glucose (G)
e. 2.8 mL penicillin/streptomycin (PS)
Note: This medium is referred to as “DMEM/F12
stock medium” throughout the protocol.
2. Twenty-four hours prior to recovery, coat a Corning T-75
flask with 5 mL of conditioned media, obtained from
previous cultures of the same hNSC cell line.
a. Place the coated flask in a 37°C incubator with 8.5%
CO2 overnight. This process will help prevent the
stem cells from adhering to the bottom of the flask
and will assist in neurosphere formation.
3. Approximately 10 minutes before seeding cells, warm
20 mL of DMEM/F12 stock medium in a 50 mL screw
cap tube in a 37°C water bath.
4. In a separate screw cap tube, warm 10 mL of DMEM/
F12 stock medium in 37°C water bath for approximately
10 minutes.
5. Obtain all media components listed in Table 1 and keep
on ice.
6. Warm 5 mL of conditioned media in 37°C water bath
for approximately 10 minutes.
7. Retrieve the tube containing the 20 mL DMEM/F12
stock medium and place in the tissue culture hood.
20
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Table 1 Growth factors for new proliferation media
Medium components

Volume per 10 mL of medium

TPPS
200 mM L-Glut

173 µL
50 µL

10 mg/mL insulin
20 µg/mL EGF
20 µg/mL bFGF
10 µg/mL Lif
5 mg/mL heparin

25 µL
10 µL
10 µL
10 µL
10 µL

Abbreviations: TPPS, transferrin, putrescine, progesterone, sodium selenite;
L-Glut, L-glutamine; EGF, epidermal growth factor; bFGF: basic fibroblast growth
factor; Lif, leukemia inhibitor factor.

a. Take 10 mL of the new media and place into a clean
screw cap tube.
8. Obtain a vial of frozen cells from the liquid nitrogen tank.
a. Quickly thaw the vial of cells in 37°C water bath and
gently invert every few seconds until fully thawed.
9. In the tissue culture hood, add the thawed cells dropwise
into 10 mL of DMEM/F12 stock medium.
10. Centrifuge the cell suspension at 200×g for 5 minutes,
and then discard supernatant.
11. Resuspend the cell pellet in additional 10 mL of DMEM/
F12 stock medium and centrifuge again at 200×g for 5
minutes.
12. During the 5-minute spin, retrieve the pre-coated flask
from the incubator and prepare the growth media by
adding the growth factors listed in Table 1 to the final
pre-heated 10 mL aliquot of DMEM/F12 stock medium.
Note: Mixture contains 100 mg/mL transferrin, 100 mM
putrescine, 20 nM progesterone, 30 nM sodium selenite.
OPTIONAL: 10% N2 supplement (Gibco).
13. Remove the conditioned media from flask and add the
5 mL of pre-heated conditioned media to the flask.
14. Retrieve the cells from the centrifuge and remove the
supernatant, leaving the cell pellet intact.
15. Resuspend cell pellet in 10 mL of freshly prepared
growth media in Step 12 and add to the T-75 flask containing pre-warmed conditioned media.
16. Firmly, but gently, rock the T-75 flask back and forth
several times to evenly distribute cells across the flask.
Loosen the cap slightly to allow airflow.
17. Under a light microscope observe the cells, make notes,
and take images if possible.
18. Return the flask to a 37°C incubator with 8.5% CO2.
Note: 8.5%, rather than 5%, CO2 is needed to keep the serumfree media at pH 7.1–7.4.

hNSC media change
1. Every 3.5 days, change the media in the T-75 flask.
2. Sterilize tissue culture hood before media change.
Journal of Neurorestoratology 2018:6
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3. Warm a 10 mL aliquot of DMEM/F12 stock medium in
37°C water bath.
4. Retrieve a container of ice and all medium components
listed in Table 1.
5. After the DMEM/F12 stock medium aliquot is warmed,
bring it into the tissue culture hood and add the growth
factors according to Table 1.
6. Gently tilt flask to the side, allowing spheres to sink to
the bottom of the flask. Look closely and carefully to
make sure spheres have sunk to the bottom of the flask
before removing any media.
7. Remove 5 mL of conditioned media from the top of the
flask, taking care not to aspirate any neurospheres.
8. Place the 5 mL of conditioned media into a clean 15 mL
tube.
9. Remove an additional 5 mL of conditioned media from
the flask and place into the same tube.
10. Add 10 mL of new media into the flask with the remaining 5 mL of conditioned media.
11. Set the flask down flat and check cell density under
microscope. If it appears that many cells were lost, centrifuge the conditioned media at 100×g for 5 minutes,
re-suspend any cells that accumulate at bottom in 1 mL
of conditioned medium, and then add to flask.
12. Store the unused conditioned media at 4°C to be used
for coating flasks at a later point in time.
13. Rock flask firmly by sliding back and forth 3–4 times
on surface of biosafety hood before loosening cap to
vent and placing in 37°C incubator with 8.5% CO2.

hNSC passage

Passage cells every 9–11 days depending on
sphere size
1. If expanding the NSCs into a new flask, make sure all new
flasks are coated 24 hours prior to seeding cells on them.
2. Clean the tissue culture hood thoroughly. Retrieve ice
and all medium components.
3. Prepare the DMEM/F12 stock medium as already
described for media changes. You will need 10 mL of
new media per flask.
4. Prepare appropriate amount of dPBS and glucose for
the trypsin solution as described in Table 2 and place
Table 2 Preparation of trypsin
Trypsin solution

Volume for
10 million cells

Volume for
30 million cells

dPBS
10% glucose
2.5% Trypsin
DNase

1 mL
60 µL
10 µL
5 µL

3 mL
180 µL
30 µL
15 µL
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in water bath to warm. Do not add trypsin or DNase at
this time.
a. One milliliter of solution for approximately 10 million cells or 3 mL for approximately 30 million cells.
5. Obtain a clean small weigh boat, a hemocytometer, and a
glass cover slip (usually sterilized and stored in 70% ethanol). Clean with 70% ethanol and allow to air dry in hood.
6. Obtain flask that will be passaged from the incubator
and bring into the tissue culture hood.
7. Tilt flask gently and remove 5 mL of conditioned media
from the top as described in the changing media procedure as already described, and put into clean 15 mL
tube labeled “CM” and the date.
8. Remove another 5 mL of medium and place in the CM
tube; be careful not to aspirate any cells.
9. Remove the remaining 5 mL of media along with the
cells and place in a clean 15 mL tube labeled as “Cells”.
10. Use the 3 mL of conditioned media in the “CM” tube
to rinse the bottom of the flask in 3 mL portions. Then,
place the 10 mL into the “Cells” tube.
a. This rinsing process helps ensure all cells will be
collected for passaging.
11. Centrifuge “Cells” at 100×g for 5 minutes.
12. While cells are spinning, obtain the dPBS/glucose
solution from 37°C water bath and add the appropriate
amount of trypsin and DNase according to Table 2.
13. After the “Cells” centrifugation is complete, remove all
supernatant and transfer it into the “CM” tube.
14. Resuspend the cell pellet in the appropriate volume of
trypsin solution and triturate the solution approximately
5–10 times, and then incubate at 37°C for 5 minutes.
Note: The amount of trypsin is depended upon the number
of cells per T-75 flask. Generally, 1 mL of trypsin is sufficient for 7–10 million of cells, and thus 3 mL per T-75.
15. During this incubation, prepare the same volume of
trypsin inhibitor that was used for the trypsin solution.
Prepare the trypsin inhibitor by placing 1–3 mL of conditioned media (same volume as the trypsin solution) in a
“Trypsin Inhibitor” labeled tube. Refer to Table 3 for the
appropriate amount of trypsin inhibitor for each volume.
a. Place trypsin inhibitor at 37°C until needed.
16. After 5 minutes, retrieve cells being trypsinized and
triturate 5–10 times, and then incubate at 37°C for an
Table 3 Preparation of trypsin inhibitor
Trypsin inhibitor

Volume for
10 million cells

Volume for
30 million cells

CM
Trypsin inhibitor

1 mL
10 µL

3 mL
30 µL
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17.

18.
19.

20.
21.

22.

23.

22

additional 10 minutes. The trituration steps are to properly dissociate the spheres.
At this time, obtain the tube of warmed DMEM/F12
stock medium and add the growth factors according to
Table 1.
In the last 5 minutes of the trypsin incubation, retrieve
the trypsin inhibitor and place in the tissue culture hood.
Retrieve the cells after the incubation time is complete
and triturate until all spheres are dissociated (approximately 20–30 times). If spheres persist, increase the
rigor of the pipetting, or pipette more.
a. If there is continual difficulty dissociating spheres,
spheres may have become too large and will be difficult to separate. Additionally, the trypsin amount
could be incorrect or the trituration process was not
vigorous enough.
Once spheres have dissociated, immediately add the
trypsin inhibitor and triturate about 5 times.
Count the number of cells by following these steps:
a. Pipette 15 µL of 0.1% trypan blue onto the small
weigh boat in a droplet form.
b. Add 5 µL cell suspension into the 15 uL droplet of
trypan blue.
c. Pipette 10 uL onto either side of a dry hemocytometer covered with the dry glass coverslip.
d. Observe the cells under a light microscope and count
the total number of cells in each of the four corner
grids.
i. Add this number together.
ii. Repeat counting for the other side.
iii. Average the two sides together.
iv. Multiply this number by 10,000, which will give
you the total number of cells per mL.
		 1. Multiply this number by the total number of
milliliters to calculate the total number of
cells in your culture.
e. Calculate how much volume of cell suspension will
be needed to seed 5 million cells in the T-75 flask.
Add the appropriate volume of cells to obtain 5 million
cells in a T-75 flask. Add enough conditioned media to
bring the final volume of cells + conditioned media to
a total of 5 mL.
a. Extra cells can be plated in other T-75 flasks at a
density of 5 million cells per flask, or these extra cells
can be placed in a T-75 flask with new media and
be frozen the next day using the methods described
later.
Add 10 mL of new media to the flask(s). The total volume
of medium will be 15 mL with 5 million cells per flask.
submit your manuscript | www.dovepress.com
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24. Rock flask firmly by sliding back and forth 3–4 times,
before loosening cap and placing in a 37°C incubator
with 8.5% CO2.

hNSC freezing and storage
1. The day after passaging, obtain the cell flask from the
incubator.
2. Remove all media and cells from the flask and place in
a 15 mL tube.
a. Make sure there are no large spheres; large spheres or
clusters of cells will not freeze well. A homogenous
cell suspension of small spheres is optimal.
3. Centrifuge at 216×g for 5 minutes.
4. During the centrifugation process, prepare freezing
media as described in Table 4. For every 5 million cells,
prepare 1 mL of freezing media.
5. Prepare cryopreserve vials with labels of:
a. Cell name
b. Passage number
c. Cell number
d. Initials
e. Date
6. After centrifugation, remove the supernatant and resuspend cell pellet in freeze media.
7. Aliquot 1 mL of cell suspension per vial and seal tightly.
8. Place vials in a cryopreserve container with isopropanol
and store at −80°C overnight, and then transfer to a
liquid nitrogen tank storage system.

Plating adherent hNSC for
immunohistochemical stains
1. The day before passaging the hNSCs, obtain a 24-well
plate and sterile glass 12 mm coverslips.
2. Using forceps, carefully place a single coverslip on the
bottom of each well of the 24-well plate.
3. Coat the wells and coverslips with 0.01% poly-D-lysine
(PDL) diluted in sterile water and incubate for 1 hour at
37°C.
4. Remove PDL and coat with 1 µg/cm2 laminin/PBS overnight at 37°C. If not needed the next day, store at 4°C.
a. Plates coated with laminin can be stored up to 2
weeks if sealed with Parafilm as long as the coverslips do not dry out.
Table 4 Preparation of freezing media
Medium components

Volume for 1 vial

Volume for 3 vials

DFHGPS
FBS 20%
DMSO 10%

0.7 mL
0.2 mL
0.1 mL

2.1 mL
0.6 mL
0.3 mL

Journal of Neurorestoratology 2018:6
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5. Passage the cells as already described and seed the cells
into the 24-well plate with coated coverslips.
a. Cells should be seeded at a density approximately
1–1.5×105 cells per well.
b. Remaining cells can be placed in a T-75 flask to
maintain the culture or frozen as already described.
6. Cells can be fixed and stained for various markers at
different times after seeding. For staining procedures
used to validate the neural stem cell phenotype, consult
the “Staining procedure” portion of this article.

ELL priming (for neuronal differentiation)
1. A total of 2–3 days before priming, passage the cells as
already described.
2. The day before priming, coat plate or flask with PDL
and laminin as already described.
3. On priming day, obtain the correct number of cells from
the flask by calculating the number of cells per mL in
the flask. Centrifuge the cell suspension to obtain a cell
pellet at 216×g for 3 minutes.
4. Prepare the priming medium during centrifuge time
according to Table 5.
5. Aspirate laminin from the wells of the plate or flask.
6. Resuspend the cell pellet with the proper volume of
priming media and load into plate or flask.
7. Incubate the plate at 37°C with 8.5% CO2 for 4 days.

FHL priming (for motor neuron
differentiation)
1. Follow the same protocol as already described; however,
make the priming media according to Table 6.

Neuronal differentiation after priming
1. Following the 4 days of priming (as already described),
prepare the differentiation media.
a. DMEM/F12 stock medium (volume varies according
to number of plates).

Table 5 ELL priming media
Medium components

Volume

DFGHPS
TPPS
200 mM L-Glut
10 mg/mL insulin
20 µg/mL EGF
10 µg/mL Lif
1 mg/mL laminin

1 mL
17.3 µL
5 µL
2.5 µL
1 µL
1 µL
1 µL

Abbreviations: ELL, epidermal growth factor, leukemia inhibitory factor, laminin;
TPPS, transferrin, putrescine, progesterone, sodium selenite; L-Glut, L-glutamine; EGF,
epidermal growth factor; Lif, leukemia inhibitor factor.

Journal of Neurorestoratology 2018:6

Table 6 FHL priming media
Medium components

Volume

DFGHPS
TPPS
200 mM L-Glut
10 mg/mL insulin
20 µg/mL bFGF
5 mg/mL heparin
1 mg/mL laminin

1 mL
17.3 µL
5 µL
2.5 µL
0.5 µL
0.5 µL
1 µL

Abbreviations: FHL, basic fibroblast growth factor; TPPS, transferrin, putrescine,
progesterone, sodium selenite; L-Glut, L-glutamine; bFGF: basic fibroblast growth
factor.

b. B27 media: 1:50 dilution, 1 part B27 media (Thermo
Fisher Scientific; category number 17504044) and 49
parts DMEM/F12 stock medium.
2. Remove the priming media from the cells and replace
with differentiation media.
3. Change media every 3.5 days.
4. Allow the cells to differentiate for 9 days.

Astrocyte differentiation
Note: The following protocol is derived from Life Technologies,
and yields approximately 90% astrocytes in a total population.
1. Two to three days prior to differentiation, passage cells.
2. Thaw a bottle of Geltrex® matrix (Thermo Fisher Scientific, Cat. No. 12760) at 4°C overnight, and then on
the next day dilute it in the ratio of 1:2 with ice cold
DMEM/F12 media to make a 100× stock.
a. Keep the bottles on ice and quickly aliquot 0.5 mL
of solution into 50 mL conical tubes, which are also
kept on ice. Store these tubes at –20°C.
3. Thaw one of the aliquots at 4°C, and add 49.5 mL of ice
cold DMEM/F12 (1:100 dilution) and then mix gently.
4. Cover the surface of each plate with the solution (1.5 mL for
a 35 mm dish, 3 mL for a 60 mm dish, 5 mL for a T-25 culture flask), and seal with parafilm to prevent evaporation.,
a. Incubate for 1 hour at room temperature in the tissue
culture hood.
5. Just before use, remove all matrix solution, rinse plates
once with sterile PBS containing calcium and magnesium, and then add the pre-warmed media (StemPro®
NSC SFM; Thermo Fisher Scientific, Waltham, MA,
USA) according to Table 7.
6. Add the NSCs to the culture dish at a density of
7×104 cells/cm2.
7. Change medium every 3–4 days.

GABA neuron differentiation
Note: The following protocol yields a population of approximately 40% GABA neurons.
submit your manuscript | www.dovepress.com
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Table 7 StemPro NSC SFM media components
Component

Final concentration

Amount

DMEM
N2 supplement
GlutaMax-I supplement
FBS

1X
1%
2 mM
1%

97 mL
1 mL
1 mL
1 mL

Note: StemPro® NSC SFM media and GlutaMax™-1 supplement are Gibco
products (Thermo Fisher Scientific, Waltham, MA, USA).

1. Follow protocol for ELL priming with the following
changes:
a. Add the following during the priming period each
day for duration of priming:
i. 10 ng/mL BMP-4 (Sigma, product number:
SRP3298).
ii. 5 µM creatine (Sigma, category number:
C0780-50G).
iii. 50 ng/mL vitamin B6 (Sigma, category number:
P9755-25G).
b. Differentiate neurons for 9–10 days in differentiation
media as previously described in the aforementioned
protocol.

Staining procedure
1. Remove media from the culture plates, and rinse once
with ice cold PBS.
2. Remove the PBS, and cover cells with ice cold 4%
paraformaldehyde. Incubate at room temperature for
20–30 minutes.
3. Remove the paraformaldehyde and rinse cells three times
with ice cold PBS, 5 minutes each.
a. At this point, you can either leave the PBS for overnight and store the plate at 4°C or begin staining
after the last rinse.
4. After PBS rinse, block the cells for 45 minutes with
a blocking solution of 5% normal serum (NS), 0.3%
bovine serum albumin (BSA), and 0.25% Triton X-100
in TBS. For example, to make 1 mL of blocking solution,
you would need:
a. 850 µL of 0.25% Triton X-100
b. 50 µL of 100% NS
c. 100 µL of 3% BSA
Note: The key of preparing the blocking solution is the
selection of a right NS, which is determined by the host
of the secondary antibody. For example, if the secondary
antibody is derived from goat, normal goat serum should
be selected.
5. During the blocking step, prepare the primary antibody
solution.
24
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7.
8.

9.

10.
11.
12.
13.

14.

15.

16.
17.
18.
19.

20.

a. For validating hNSCs, proteins such as Nestin and
Sox2 can be targeted using the appropriate antibody
against them.
b. For differentiation, markers such as MAP2 can be
used to identify neuronal populations, while glial
fibrillary acidic protein (GFAP) can be used to
identify astrocytes.
c. Various markers for specific neuronal cell types can
also be used for further characterization of the cells.
To prepare the primary antibody solution, keep all
reagents on ice.
Centrifuge the primary antibody at 12,000×g for 2
minutes at 4°C.
Place the appropriate amount of antibody in an ice
cold 0.25% Triton X-100 solution to reach the desired
concentration.
Add appropriate amount of antibody solution to each
well, for example, approximately 300 µL for each well
in a 24-well plate.
Incubate the cells with primary antibody for 2 hours at
room temperature or overnight at 4°C.
After the incubation, wash cells with TBS three times
at room temperature for 10 minutes each.
Centrifuge the secondary antibody at 12,000×g for
2 minutes at 4°C.
IMPORTANT: From now onward, all steps must be
conducted in a darkened room, and antibody and cells
should be protected from light as much as possible.
Dilute the appropriate fluorescent secondary antibody
(such as Alexa Fluor) to the recommended concentration
(Alexa Fluor is typically 1:500) in 0.25% Triton X-100
solution.
After the final TBS wash, add 300 µL of the secondary
antibody solution to each well and incubate in the dark
for at least 1 hour at room temperature.
After the incubation, wash the cells three times with
TBS for 10 minutes each.
Dilute DAPI nuclear stain to recommended concentration in TBS (typically 1:5,000).
After the final wash, add 300 µL of DAPI solution to each
well and incubate for 5 minutes at room temperature.
Rinse with TBS once before using a fluorescent mounting media such as Fluoromount G to mount the coverslips by placing a thin line of media on a glass slide.
Carefully use tweezers to remove coverslips from the
24-well plate wells and place the cell surface down on
the mounting media on the slide.
a. Make sure to label slides with all relevant information needed to identify the cells on that slide.
Journal of Neurorestoratology 2018:6
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21. Once the cells are on the slide, place the slide in a flat
slide holder.
22. Cover the holder with aluminum foil to keep light away
from the slides.
23. Store the slides at 4°C and allow the mounting media
to solidify overnight.
24. The following day, observe the slide using a fluorescent
microscope.

Representative results
Cultured hNSCs in their proliferative stage will grow as nonadherent neurospheres (Figure 1). Immediately following
hNSC passage, there will be many individual cells, which, in
the next few days, will aggregate and begin to form spheres.
At 9–10 days following a passage, healthy spheres should
be approximately 0.5–1 mm in diameter. Spheres that grow
larger than 2 mm will develop a dark center, and the growth
factors in the media will not be able to reach the cells in the
center of the sphere, resulting in unwanted differentiation.
Healthy spheres will appear translucent and display pseudocilia around the edges of the sphere (Figure 1).
Plating neurospheres on an adherent surface for differentiation purposes will result in growth of an adherent culture
(Figure 2). Priming and differentiating the cells require the
cells to adhere to a coverslip at the bottom of a cell culture
plate, such as a 24-well plate. The cells start to migrate out
after priming and differentiating. The migration pattern is
apparently different between ELL priming (Figure 2A) and
FHL priming (Figure 2B).
To identify and confirm the phenotype of neurons or
astrocytes generated from the differentiation experiments,

Figure 1 Representative bright field image of hNSC sphere in culture.
Note: Scale bar, 60 µm.
Abbreviation: hNSC, human fetal brain neural stem cell.

Journal of Neurorestoratology 2018:6
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various fluorescent immunohistochemistry can be used.
GABAergic or glutamatergic neurons can be stained using
GABA or glutamate-specific antibodies in ELL-primed and
differentiated cells, respectively (Figure 2C–D). Following
FHL priming, more motor neurons are expected and therefore choline acetyltransferase can be used to identify this
population (Figure 2E). These results provide an example
representation of immunocytochemical findings. Full immunocytochemical and electrophysiological characterization of
these cells has been previously published, and can be referred
to for additional neuronal markers and electrophysiological
profile.9 Although the priming step is used to achieve a higher
percentage of neurons following differentiation, there will
still be astrocytes in the culture. GFAP can be used to label
astrocytes in order to quantify which percentage of differentiated cells became astrocytes or neurons. Additionally,
GFAP can be used to identify astrocytes following enriched
astrocyte differentiation (Figure 2F).

Discussion
In this protocol, we have described key steps and considerations for reducing variability in culturing methods in order
to obtain a productive hNSC culture. The ability to culture
and manipulate hNSCs provides a critical tool that can be
used for a variety of purposes from modeling human disease
to high throughput drug screening.6–7,10–12 One of the challenges with hNSC culture is maintaining the “stemness” of
the culture. Svendsen et al developed a method in 1998 to
maintain primary human fetal neural stem cells in culture
by chopping neurospheres into pieces.8 Svendsen’s protocol
has been used and adjusted in a number of laboratories. In
our protocol, half the amount of FGF and heparin is used.
In addition, we developed a way to completely dissociate
neurospheres into single cells, which allows us to propagate
hNSCs for about 100 passages and with minimal chromosomal alteration.7,9 Another crucial part of culturing hNSCs is
the passaging step. This step is the source of many errors. It
is important to note if there are many dead or non-dissociated
cells following the trypsinization process. If there are many
dead cells, reduce the number of times of pipetting up and
down during dissociation, as too much mechanical stress can
result in cell death. Alternatively, if large amounts of clustered
cells remain, the dissociation will have to be more vigorous,
as these clusters will quickly become large spheres that will
promote cell differentiation in culture.
Using the aforementioned protocol, hNSCs were propagated and then transplanted into the brains of mice following
traumatic brain injury, which resulted in decreased accumulation of amyloid precursor protein.13 This transplantation
submit your manuscript | www.dovepress.com
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Figure 2 Representative bright field and fluorescent images of hNSCs following various differentiation treatments.
Notes: (A) Adherent neuron culture following ELL priming. (B) Adherent neuron culture following FHL priming. (C) GABAergic neurons with GABA staining (red) in
neurons generated from ELL priming and differentiation (DAPI nuclear marker in blue). (D) Glutamatergic neurons with glutamate staining (red) in neurons generated from
ELL priming and differentiation (DAPI nuclear marker in blue). (E) Motor neurons with ChAT staining (red) in neurons generated from FHL priming and differentiation
(DAPI nuclear marker in blue). (F) Astrocytes stained with GFAP following astrocyte differentiation. Scale bars: 50 µm in bright field images, 20 µm in fluorescent images.
Abbreviations: hNSC, human fetal brain neural stem cell; ChAT, choline acetyltransferase; GFAP, glial fibrillary acidic protein; DAPI, 4',6-diamidino-2-phenylindole,
dihydrochloride; ELL, epidermal growth factor, leukemia inhibitory factor, laminin; FHL, basic fibroblast growth factor.

reduced microglial activation and diminished inflammatory
mediators.13 These results pose further interesting applications of hNSC culture for transplantation and mediation of
glial responses. The role of glial progenitors and transplantation is critically important due to their proven role in rescuing
myelination phenotype in mice.14–16
NSCs play pivotal roles in everything from infection to
psychiatric disorders. Multiple studies from our lab have
utilized these hNSC culture and differentiation techniques
26
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to improve efficacy of stem cell transplantation in the context of traumatic brain and spinal cord injury.9,17,18 We have
also used hNSC culture to investigate Zika virus-associated
neuropathology.7 Since these hNSCs are not genetically
modified and isolated from individual donors, it is possible to
investigate factors that impact how individuals will respond
to various stimuli such as Zika virus.7 In vitro studies using
hNSCs not only provide unique insight into basic stem cell
behavior, but also provide an excellent platform to conduct
Journal of Neurorestoratology 2018:6
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pre-clinical research. Recently, this hNSC culture system was
used to screen FDA-approved drugs to prevent Zika virus
infection of NSCs.6,7
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